Value
9.6/10data confidence 20%| Component | Sub-score |
|---|---|
| P/E | 9.6 |
- ▸Attractively valued
BME · Why this verdict
Why Blackrock Health Sciences Trust (BME) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score6.2/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
BME shows a wide margin of safety and best-in-class margins within a wide-moat, compounding business, but earnings quality warnings, a Rule of 40 failure, and an overbought setup near a 52-week high leave upside already exhausted by the engine's own gates.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The fund carries an earnings quality red flag with free cash flow at -3% of net income, even though it is otherwise described as having a wide economic moat with strong returns and growth characteristic of a business that compounds capital over time. Quality breakdown | The FCF-to-net-income ratio should turn positive over the next 12 months for the earnings quality red flag to clear. | →Stable |
| CounterA wide economic moat and strong combined returns-and-growth profile suggest the underlying business quality remains intact despite the near-term FCF conversion issue. | ||
The fund shows a 51% margin of safety alongside an attractive valuation reading, the strongest bull signals in the data. Bull case | The margin of safety should persist or widen further over the next 12 months as the discount to intrinsic value is realized in price. | →Stable |
| CounterA margin of safety this wide for a health sciences trust can also reflect a structurally discounted NAV that the market never closes. | ||
The fund sits just 0.4% from its 52-week high with the engine's own asymmetry gate flagging upside as exhausted at 0.0%. Gates warning | A new resistance level should open up at least 10% of fresh upside over the next 12 months for the asymmetry gate to clear. | →Stable |
| CounterPositive momentum and rising on-balance volume both point to continued strength that could carry price to new highs despite the exhausted upside reading. | ||
The fund fails the Rule of 40 test at -18, well below the 40 threshold that would indicate a healthy balance of growth and profitability. Quality breakdown | The Rule of 40 score should climb back above 0 over the next 12 months for the failing grade to lift. | →Stable |
| CounterRule of 40 is designed for growth companies and may not be a meaningful measure for an income-oriented health sciences trust. | ||
The fund is overbought with an RSI of 82 while trading above its 200-day moving average and near its 52-week high, a combination that historically precedes a pullback. Momentum breakdown | RSI should cool from 82 toward the 50-70 range while price holds above the 200-day moving average over the next 12 months. | →Stable |
| CounterRising on-balance volume alongside the overbought reading shows genuine accumulation, which can sustain a rally even from stretched conditions. | ||
The fund carries an earnings quality red flag with free cash flow at -3% of net income, even though it is otherwise described as having a wide economic moat with strong returns and growth characteristic of a business that compounds capital over time.
→StableQuality breakdown
- Expectation
- The FCF-to-net-income ratio should turn positive over the next 12 months for the earnings quality red flag to clear.
CounterA wide economic moat and strong combined returns-and-growth profile suggest the underlying business quality remains intact despite the near-term FCF conversion issue.
The fund shows a 51% margin of safety alongside an attractive valuation reading, the strongest bull signals in the data.
→StableBull case
- Expectation
- The margin of safety should persist or widen further over the next 12 months as the discount to intrinsic value is realized in price.
CounterA margin of safety this wide for a health sciences trust can also reflect a structurally discounted NAV that the market never closes.
The fund sits just 0.4% from its 52-week high with the engine's own asymmetry gate flagging upside as exhausted at 0.0%.
→StableGates warning
- Expectation
- A new resistance level should open up at least 10% of fresh upside over the next 12 months for the asymmetry gate to clear.
CounterPositive momentum and rising on-balance volume both point to continued strength that could carry price to new highs despite the exhausted upside reading.
The fund fails the Rule of 40 test at -18, well below the 40 threshold that would indicate a healthy balance of growth and profitability.
→StableQuality breakdown
- Expectation
- The Rule of 40 score should climb back above 0 over the next 12 months for the failing grade to lift.
CounterRule of 40 is designed for growth companies and may not be a meaningful measure for an income-oriented health sciences trust.
The fund is overbought with an RSI of 82 while trading above its 200-day moving average and near its 52-week high, a combination that historically precedes a pullback.
→StableMomentum breakdown
- Expectation
- RSI should cool from 82 toward the 50-70 range while price holds above the 200-day moving average over the next 12 months.
CounterRising on-balance volume alongside the overbought reading shows genuine accumulation, which can sustain a rally even from stretched conditions.
Per-dimension breakdown
Quality
4.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 4.6 |
| ROA | 0.1 |
| Gross margin | 10.0 |
| Op margin | 8.1 |
| Current ratio | 0.9 |
| FCF quality | 0.0 |
| Moat | 7.8 |
| Rule of 40 | 3.0 |
| Piotroski F | 6.7 |
- ▸Earnings quality RED FLAG: -3% FCF/NI
- ▸Wide economic moat
- ▸Compounder quality: strong returns + growth
- ▸Rule of 40: -18 (fail)
Growth
4.4/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 4.4 |
Momentum
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 8.1 |
| MACD | 0.6 |
| OBV | 10.0 |
| MA position | 6.0 |
| Volume | 3.9 |
- ▸Uptrend pullback (RSI 34) - buy opportunity
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
5.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
7.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.9 |
| quality rank | 8.3 |
| growth rank | 6.9 |
- ▸Best-in-class margins
- ▸Conservative debt levels
Technical
6.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 6.1 |
| support resistance | 4.7 |
| 52w position | 9.2 |
Risk (lower is worse)
9.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 9.8 |
| days to cover | 9.8 |
| volatility | 8.8 |
| beta | 9.5 |
| debt equity | 10.0 |
Catalyst
6.0/10data confidence 25%| Component | Sub-score |
|---|---|
| dividend safety | 6.0 |
- ▸Yield trap warning: high yield but unsafe
How the verdict was assembled
Engine trigger
Mixed signals. Hold existing position.
Engine technical detail
verdict_path:
L4:PATH_F_HOLD_DEFAULTPassed (7)
- MOMENTUM:5.7>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
Reward-to-Risk
0.00
Upside
+0.0%
Downside
5.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.5B) below institutional reach
SuitabilityAggressive — MCap $0.5B<$5B
Investment implication
The default F-path HOLD fired without any positive-conviction gate triggering — no momentum acceleration, no quality+value crossover, no setup recognition. Highest-clear gate: MOMENTUM:5.7>=5.5. Top dim: Value at 9.6; weakest: Growth at 4.4. The engine's read is one of pattern absence — no directional conviction in either direction at current asymmetry.
The strongest dimensions are Value at 9.6, Risk (lower is worse) at 9.6, and Peer rank at 7.2; the weakest are Growth at 4.4, Quality at 4.6, and Insider at 5.0. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Margin Of Safety And Attractive Valuation
Trip ifMargin of safety compresses below 15% from the current 51%.
- P2Near 52 Week High Upside Exhausted
Trip ifA new resistance level opens upside exceeding 10% from the current 0.0%.
- P3Earnings Quality Red Flag Despite Moat
Trip ifFCF-to-net-income ratio rises above 10% from the current -3%.
- P4Rule Of 40 Failure
Trip ifRule of 40 score rises above 0 from the current -18.
- P5Overbought Momentum At Highs
Trip ifRSI stays above 80 for more than 4 consecutive weeks without a pullback.